When would you consider neoadjuvant immunotherapy for advanced melanoma?
For example, would you consider this in a patient that would otherwise be eligible for adjuvant treatment (stage III or stage IV with oligometastatic disease)? Would you consider doing so based on limited data from Safety, activity, and biomarkers for neoadjuvant anti-PD-1 therapy in melanoma and/or extrapolating from recent NSCLC data?
1 Answer
Mednet Member
Medical Oncology · University of Pittsburgh School of Medicine
Answered on
Neoadjuvant immunotherapy is a reasonable if investigational approach to melanoma. The role of neoadjuvant therapy as an investigative approach lies in its ability to give both efficacy information and Biomarker information. We have published encouraging results with interferons 12 years ago, (Mosch...
Join for free or sign in to see the full answer